Giacchino R, Facco F, Giambartolomei G, Navone C, Timitilli A, Cirillo C, Barigione G, Terragna A
Clinica Malattie Infettive, Università di Genova, Italy.
Chemioterapia. 1988 Dec;7 Suppl 3:20-5.
The efficacy of human lymphoblastoid interferon (Wellferon) therapy was measured in 20 children with chronic hepatitis B with or without pretreatment with prednisolone. Patients were randomised to receive 0.6 mg/kg/day prednisolone for 3 weeks, then at 0.3 mg/kg for a fourth week or placebo. All patients then received interferon 5 MU/m2 i.m. for 12 weeks; daily for 5 days then three times a week for the remaining 11 weeks. Preliminary results show that 25% of children had a permanent loss of viral markers of replication. However, response to interferon varied widely between individuals and a prolonged follow-up is required in order to determine the influence of prednisolone pretreatment on the efficacy of interferon therapy.
在20例慢性乙型肝炎患儿中测量了人淋巴母细胞干扰素(Wellferon)疗法的疗效,这些患儿有的接受了泼尼松龙预处理,有的未接受。患者被随机分为两组,一组接受3周的0.6mg/kg/天泼尼松龙治疗,然后第4周接受0.3mg/kg剂量,另一组接受安慰剂。所有患者随后接受12周的5MU/m²干扰素肌肉注射治疗;前5天每天注射,其余11周每周注射3次。初步结果显示,25%的患儿出现病毒复制标志物的永久性消失。然而,个体对干扰素的反应差异很大,需要进行长期随访以确定泼尼松龙预处理对干扰素治疗疗效的影响。